J. Black

发表

SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression

E. Ratner, Serena Wong, D. Silasi, 2016, Molecular Cancer Therapeutics.

SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression.

Gloria S. Huang, E. Ratner, Serena Wong, 2017, Gynecologic oncology.

T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2

S. Canevari, P. Schwartz, T. Rutherford, 2014, Clinical & Experimental Metastasis.

Outcomes and relapse patterns of stage IB grade 2 or 3 endometrial cancer treated with adjuvant vaginal brachytherapy

P. Schwartz, J. Kelly, S. Higgins, 2019, International Journal of Gynecological Cancer.

Ten-Year Comparison Study of Type 1 and 2 Endometrial Cancers: Risk Factors and Outcomes

E. Ratner, D. Silasi, P. Schwartz, 2019, Gynecologic and Obstetric Investigation.

The management of sexuality, intimacy, and menopause symptoms (SIMS) after prophylactic bilateral salpingo-oophorectomy: How to maintain sexual health in "previvors".

E. Ratner, J. Black, M. J. Minkin, 2017, Maturitas.

SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression

E. Ratner, Serena Wong, D. Silasi, 2017, Clinical Cancer Research.

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas

E. Ratner, D. Silasi, P. Schwartz, 2015, British Journal of Cancer.

Should we continue intra-peritoneal chemotherapy in advanced ovarian cancer patients?

J. Black, G. Menderes, M. Azodi, 2016 .

Isolated port site recurrence of node-negative clinical stage IB1 cervical adenocarcinoma

M. Azodi, P. Hui, Molly McAdow, 2017, Gynecologic oncology reports.

Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo.

E. Ratner, D. Silasi, P. Schwartz, 2015, Gynecologic oncology.

Surgical Site Infections in Gynecology

Sangini S. Sheth, J. Black, C. de Haydu, 2014, Obstetrical & gynecological survey.

Management of sexuality, intimacy, and menopause symptoms in patients with ovarian cancer

E. Ratner, J. Black, G. Menderes, 2017, American journal of obstetrics and gynecology.

Developments in the Biology of Neuroblastoma: Implications for Diagnosis and Treatment

J. Black, J. Kemshead, 1980, Developmental medicine and child neurology.

Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial–mesenchymal transition

S. Mane, T. Boggon, Kaya Bilgüvar, 2016, Proceedings of the National Academy of Sciences.

Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo

E. Ratner, R. Angioli, D. Silasi, 2015, Molecular Cancer Therapeutics.

Dual HER 2 / PIK 3 CA Targeting Overcomes Single-Agent Acquired Resistance in HER 2-Ampli fi ed Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo

E. Ratner, R. Angioli, D. Silasi, 2015 .

Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo

Pei Hui, Jonathan Black, David L Rimm, 2016, British Journal of Cancer.

The Role of the Immune System in Ovarian Cancer and Implications on Therapy

A. Santin, J. Black, G. Menderes, 2016, Expert review of clinical immunology.

Polymerase ε (POLE) ultra-mutated tumors induce robust tumor-specific CD4+ T cell responses in endometrial cancer patients.

E. Ratner, D. Silasi, P. Schwartz, 2015, Gynecologic oncology.

Immunotherapy and targeted therapy for cervical cancer: an update

A. Santin, J. Black, G. Menderes, 2016, Expert review of anticancer therapy.

Molecular diagnosis and molecular profiling to detect treatment-resistant ovarian cancer

Jonathan Black, A. Santin, J. Black, 2016, Expert review of molecular diagnostics.

Objective, domain-specific HER2 measurement in uterine and ovarian serous carcinomas and its clinical significance

D. Rimm, K. Schalper, A. Santin, 2017, Gynecologic oncology.

Immune checkpoint inhibitors in gynecologic cancers with lessons learned from non-gynecologic cancers

A. Santin, J. Black, G. Menderes, 2016, Expert opinion on biological therapy.

Impact of carboplatin hypersensitivity and desensitization on patients with recurrent ovarian cancer

Gloria S. Huang, E. Ratner, D. Silasi, 2018, Journal of Cancer Research and Clinical Oncology.

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas

E. Ratner, D. Silasi, P. Schwartz, 2015, British Journal of Cancer.

Future Directions and New Targets in Endometrial Cancer

L. Gold, A. Santin, J. Black, 2015 .

An update on the current pharmacotherapy for endometrial cancer

A. Santin, J. Black, Carlton L. Schwab, 2016, Expert opinion on pharmacotherapy.

Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro

E. Ratner, D. Silasi, P. Schwartz, 2015, Tumor Biology.

Targeted Therapy in Uterine Serous Carcinoma: An Aggressive Variant of Endometrial Cancer

A. Santin, J. Black, D. Roque, 2014, Women's health.

T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2

S. Canevari, P. Schwartz, T. Rutherford, 2014, Clinical & Experimental Metastasis.

A Series of Malignant Ovarian Cancers Arising From Within a Mature Cystic Teratoma: A Single Institution Experience

E. Ratner, P. Schwartz, T. Rutherford, 2015, International Journal of Gynecologic Cancer.

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas

E. Ratner, D. Silasi, P. Schwartz, 2015, British Journal of Cancer.

Robotic Versus Laparoscopic Hysterectomy for Benign Disease: A Systematic Review and Meta-Analysis of Randomized Trials.

J. Black, Elisabeth A Erekson, Benjamin B Albright, 2016, Journal of minimally invasive gynecology.

An unexpected mass of the urachus: a case report.

M. Azodi, J. Black, N. Buza, 2014, American journal of obstetrics and gynecology.

Uterine Didelphys and Vaginal Birth After Cesarean Delivery

J. Black, A. Sfakianaki, G. Altwerger, 2015, Obstetrics and gynecology.

Management of Borderline Ovarian Tumors Based on Patient and Tumor Characteristics

E. Ratner, D. Silasi, P. Schwartz, 2015, Gynecologic and Obstetric Investigation.

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas

N. Rothman, Q. Lan, E. Ratner, 2015, British Journal of Cancer.

Polymerase ε (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro.

E. Sartori, E. Ratner, D. Silasi, 2017, Gynecologic oncology.

Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression.

Gloria S. Huang, E. Ratner, Serena Wong, 2017, Gynecologic oncology.

The role of minimally invasive interval debulking surgery in advanced epithelial ovarian cancer

J. Black, G. Menderes, M. Azodi, 2016, Expert review of anticancer therapy.

Dual-Targeting Nanoparticles for In Vivo Delivery of Suicide Genes to Chemotherapy-Resistant Ovarian Cancer Cells

E. Ratner, W. Saltzman, D. Silasi, 2016, Molecular Cancer Therapeutics.

Clostridium Perfringens Enterotoxin (CPE) and CPE-Binding Domain (c-CPE) for the Detection and Treatment of Gynecologic Cancers

E. Cocco, A. Santin, J. Black, 2015, Toxins.

Correction of coagulopathy associated with non-bacterial thrombotic endocarditis (NBTE) by surgical debulking in a case of ovarian clear cell carcinoma

P. Schwartz, J. Black, N. Vilardo, 2016, Gynecologic oncology reports.

Efficacy of neratinib in the treatment of HER2/neu-amplified epithelial ovarian carcinoma in vitro and in vivo

E. Ratner, D. Silasi, P. Schwartz, 2017, Medical Oncology.

Clostridium perfringens enterotoxin C‐terminal domain labeled to fluorescent dyes for in vivo visualization of micrometastatic chemotherapy‐resistant ovarian cancer

C. Zeiss, E. Ratner, W. Saltzman, 2015, International journal of cancer.

Associated characteristics and impact on recurrence and survival of free-floating tumor fragments in the lumen of fallopian tubes in Type I and Type II endometrial cancer

E. Ratner, D. Silasi, P. Schwartz, 2018, Gynecologic oncology reports.

Adjuvant Hormonal Therapy for Low-Grade Endometrial Stromal Sarcoma

E. Ratner, D. Silasi, P. Schwartz, 2018, Reproductive Sciences.

Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro.

E. Ratner, D. Silasi, P. Schwartz, 2016, American journal of obstetrics and gynecology.

Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro

E. Ratner, D. Silasi, P. Schwartz, 2015, Journal of experimental & clinical cancer research : CR.

The use of QuikClot combat gauze in cervical and vaginal hemorrhage

E. Ratner, J. Black, J. Feinberg, 2017, Gynecologic oncology reports.

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas

E. Ratner, D. Silasi, P. Schwartz, 2015, British Journal of Cancer.

The role of minimally invasive interval debulking surgery in advanced epithelial ovarian cancer

J. Black, G. Menderes, M. Azodi, 2016, Expert review of anticancer therapy.

The management of sexuality, intimacy, and menopause symptoms (SIMS) after prophylactic bilateral salpingo-oophorectomy: How to maintain sexual health in "previvors".

E. Ratner, J. Black, M. J. Minkin, 2017, Maturitas.

Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro

E. Ratner, D. Silasi, P. Schwartz, 2015, Journal of experimental & clinical cancer research : CR.

E. Ratner, D. Silasi, P. Schwartz, 2015, Tumor Biology.